Compare Ecolab Inc. (ECL) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Ecolab Inc. trades at $288.75 (market cap $80.65B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Ecolab Inc. is far larger — about 16.1× Travere Therapeutics Inc. Common Stock's market cap, and Ecolab Inc. pays a 1.01% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 91 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ECL | TVTX | |
|---|---|---|
Market Cap | $80.65B | $5.02B |
Volume | 847,309 | 2,060,842 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $67.52 |
52-Week Low | $245.73 | $26.79 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $89.44B | $5.15B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $285.66, up 0.48% today, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $16.08B in 2025, with a net income margin of 12.57% and robust profitability metrics. Recent news highlights its dividend aristocrat status and growth in high-tech and digital segments, with Q3 2026 earnings anticipated on October 27, 2026.
The outlook remains positive given analyst consensus and a $326.38 price target, though risks include elevated valuation multiples and increased debt from recent acquisitions. Earnings growth and contract renewal resilience underpin the investment case, but cost fluctuations and execution risks warrant monitoring.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
